The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.
In letters, CRISPR companies respond to a Nature Methods report of off-target editing effects, Technology Review reports.
UC can still salvage its CRISPR IP rights after last week's decision, but a long-shot appeal in federal court is the only possibility for total victory.
The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.
The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
The gene editing firm will concurrently offer 5 million shares to the public and $55 million worth of shares at the same price in a private placement.
The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.